Organisation

• Stammzelltransplantation
• Immunzelltherapien
• Chimärische Antigenrezeptor T Zellen
• Apheresen
• Sprechstunde, Beratung und Zweitmeinung nach Vereinbarung

• Experimentelle Stammzelltransplantation
• Graft-vs-Host Erkrankung
• Immunrekonstitution nach Transplantation

Original Papers

• Bankova AK, Pasin C, Huang A, Cicin-Sain C, Epp S, Audige A, Mueller NJ, Nilsson J, Vilinovszki O, Nair G, Wolfensberger N, Hockl P, Schanz U, Trkola A, Kouyos R, Hasse B, Zinkernagel AS, Manz MG, Abela IA, Müller AMS Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation. Br J Haematol. 2022 Nov 16. doi: 10.1111/bjh.18562
• Ruder J, Docampo MJ, Rex J, Obahor S, Naghavian R, Müller AMS, Schanz U, Jelcic I, Martin R. Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis. Sci Transl Med. 2022 Nov 2;14(669):eabq1693. doi: 10.1126/scitranslmed.abq1693
• Ruder JF, Dinner G, Maceski AM, Correa EB, Müller AM, Jelcic I, Kuhle J, Martin R. Dynamics of inflammatory and neurodegenerative bi-omarkers after autologous hematopoietic stem cell transplantation in multiple sclerosis. Int J Mol Sci. 2022 Sep 19;23(18):10946. doi: 10.3390/ijms231810946
• Ring A, Grob B, Aerts E, Ritter K, Volbracht J, Schär B, Greiling M, Müller AMS. Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma. Annals of Hematology, published online June 27^th 2022, doi.org/10.1007/s00277-022-04881-0
• Sebastian Stolz, Marco Roncador, Wiebke Rösler, Thorsten Zenz, Markus G. Manz, Antonia M.S. Müller*, Corinne C. Widmer. Introducing innovative cellular therapies into the clinic: a 2-year retrospective analysis of chimeric antigen receptor T-cell experience at a single center in Switzerland; accepted for publication SMW
• Huang A, Cicin-Sain C, Pasin C, Epp S, Audigé A, Müller NJ, Nilsson J, Bankova A, Wolfensberger N, Vilinovszki O, Nair G, Hockl P, Schanz U, Kouyos RD, Hasse B, Zinkernagel AS, Trkola A, Manz MG, Abela IA, Müller AMS. Antibody Response to SARS-CoV-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jan 26:S2666-6367(22)00039-2. doi: 10.1016/j.jtct.2022.01.019. Online ahead of print. PMID: 35092892
• Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMoa2116596. Online ahead of print. PMID: 34904798
• Krieg S, Seeger H, Hofmann P, Del Prete C, Manz MG, Müller AM, Theocharides APA. Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia. Br J Haematol. 2022 Feb;196(3):781-784. doi: 10.1111/bjh.17854. Epub 2021 Oct 5. PMID: 34611894
• Ruder J, Rex J, Obahor S, Docampo MJ, Müller AMS, Schanz U, Jelcic I, Martin R. NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Front Immunol. 2021 Dec 16;12:794077. doi: 10.3389/fimmu.2021.794077. eCollection 2021. PMID: 34975899
• Rieger MJ, Stolz SM, Ludwig S, Benoit TM, Bissig M, Widmer CC, Schwotzer R, Müller AM, Nair G, Hegemann I, Manz MG, Schanz U. Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. Br J Haematol. 2021 Sep;194(5):931-934. doi: 10.1111/bjh.17655. Epub 2021 Jun 28. PMID: 34180543
• Linnik J, Syedbasha M, Kaltenbach HM, Vogt D, Hollenstein Y, Kaufmann L, Cantoni N, Ruosch-Girsberger S, Müller AMS, Schanz U, Müller Pabst T, Stüssi G, Weisser M, Halter J, Stelling J, Egli A. (2021) Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant (HSCT) patients. J Infect Dis. 2021 Aug 20. Online ahead of print. PMID: 34415049
• Diem-Lan Vu, Julie-Anne Dayer, Stavroula Masouridi-Levrat, Christophe Combescure, Elsa Boely, Nina Khanna, Nicolas J Mueller, Martina Kleber, Michael Medinger, Joerg Halter, Jakob Passweg, Antonia M Müller, Urs Schanz, Yves Chalandon, Dionysios Neofytos, Christian van Delden, Laurent Kaiser, Swiss Transplant Cohort Study (2020) Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5‐year analysis within the Swiss Transplant Cohort study. Transpl Infect Dis 22(4) Epub 2020 Apr 27 – IF 2.071
• Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nuñez N, Simonis A, Pfister S, Wilk CM, McHugh D, Friemel J, Müller AM, Becher B, Münz C, van den Broek M, Neri D, Manz MG (2020) Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34:2688-2703. Epub 2020 May 1 – IF 8.665
• Bögeholz J, Russkamp NF, Wilk CM, Gourri E, Haralambieva E, Schanz U, Mueller NJ, Manz MG, Müller AMS (2020) Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. Mar;26:581-592. – IF 3.853
• Müller AMS, Min D, Wernig G, Levy RB, Perez VL, Herretes S, Florek M, Burnett C, Weinberg K, Shizuru JA (2019) Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets. Biol Blood Marrow Transplant 25(12):2338-2349 – IF 3.853
• Guido Ghilardi, Beatrice Mueller, Barbara Jeker, Rouven Müller, Anne Cairoli, Antonia Müller, Mario Bargetzi, Felicitas Hitz, Dominik Heim, Adrian Schmidt, Davide Rossi, Michele Ghielmini, Luciano Wannesson, Erika Lerch, Panagiotis Samaras, Urs Schanz, J Passweg, Georg Stussi, Martina Kleber, Bernhard Gerber (2019) Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multi-centric observational registry study. Bone Marrow Transplant. 54(7):1029-1037 – IF 4.725
• Simonis A, Fux M, Nair G, Mueller NJ, Haralambieva E, Pabst T, Pachlopnik Schmid J, Schmidt A, Schanz U, Manz MG, Müller AMS (2018) Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency-a case report and comprehensive review of the literature. Ann Hematol. 97(10):1961-1973 – IF 2.904
• Samaras P, Rütti MF, Seifert B, Bachmann H, Schanz U, Eisenring M, Renner C, Susanne Müller AM, Schmidt A, Mischo A, Fuchs I, Bargetzi M, Manz MG, Stupp R, Petrausch U, Stenner-Liewen F. (2018) Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study. Biol Blood Marrow Transplant. 24(4):694-699 – IF 3.853
• Mathew NR, Baumgartner F, Braun L, O´Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T,Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D (DH), Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R (2018) Sorafenib promotes graft-versus-eukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. Nature medicine, 24(3):282-291 – IF 36.130
• Passweg JR, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Güngör T, Halter J, Heim D, Hess U, Leibundgut U, Müller A, Nair G, Pabst T, Renner C, Stuessi G, Nicoloso de Faveri G, Schanz U for the Swiss Blood Stem Cell Transplantation Group (SBST). (2018) Hematopoetic Cell Transplantation in Switzerland, Changes and Results over 20 years. A report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation (SBST) Registry 1997-2016. Swiss Med Wkly, 148:w14589 – IF 1.822
• Wilk CM, Weber I, Seidl K, Rachmühl C, Holzmann-Bürgel A, Müller AM, Kuster SP, Schanz U, Zinkernagel AS (2017) Impact of oral gut decontamination on Staphylococcus aureus colonization in patients undergoing allogeneic hematopoietic stem cell transplantation International Journal of Antimicrobial Agents. Int J Antimicrob Agents, 50(6):726-729 – IF 4.621
• Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA (2016) Blood stem cell activity is arrested by T_H1-mediated injury preventing engraftment following non-myeloablative conditioning. Journal of Immunology, 197(10):4151-4162 – IF 4.886
• Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S (2015) Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete. Clin Cancer Res 15;21(16):3727-39 – IF 10.107
• Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA (2014) Donor hematopoiesis in mice following total lymphoid irradiation requires host T regulatory cells for durable engraftment. Blood 123:2882-2892 – IF 17.794
• Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R (2014) Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation 124:2668-2682 – IF 11.864
• Filatenkov A, Baker J, Müller AM, Ahn G-O, Kohrt HE, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S (2014) Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion. Radiation Research 182:163-169 – IF 2.657
• Florek M, Sega EI, Leveson-Gower D, Baker J, Müller AM, Meyer E, Negrin RS (2014) Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. Blood 124:1832-1842 – IF 17.794
• Ali SR, Ranjbarvaziri S, Talkhabi M, Subat A, Volz K, Zhao P, Müller AM, Red-Horse K, Weissman IL, Ardehali R (2014) Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circulation Research 115:625-635 – IF 14.467
• Müller AM, Shashidhar S, Küpper N, Kohrt HE, Florek M, Negrin R, Brown J, Shizuru JA (2012) Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proceedings of the National Academy of Sciences (PNAS) USA 109:5820-5825 – IF 9.412
• Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino A, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA (2012) Long-term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. Biology of Blood and Marrow Transplantation 18:125-133 – IF 3.853
• Kohrt HE, Müller AM, Baker J, Goldstein MJ, Newell E, Dutt S, Czerwinski D, Lowsky R, Strober S (2011) Donor immunization with WT1 peptide augments anti-leukemic activity after MHC-matched bone marrow transplantation. Blood 118:5319-5329 – IF 17.794
• Kohrt HE, Houot R, Goldstein M, Weiskopf K, Alizadeh AA, Brody J, Müller AM, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder T, Levy R (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:2423-2432 – IF 17.794
• Udi J, Wider D, Kleber M, Ihorst G, Müller AM, Wäsch R, Engelhardt M (2011) Endothelial progenitor cells, hemangioblasts and VEGFR2⁺-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments. Leukemia Research 35:1265-1268 – IF 2.214
• Müller AM, Linderman JA, Florek M, Miklos D, Shizuru JA (2010) Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences (PNAS) USA 107:14721-14726 – IF 9.412
• Filatenkov A, Müller AM, Tseng WW, Dejbakhsh-Jones S, Winer D, Luong R, Shizuru JA, Engleman EG, Strober S (2009) Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. Journal of Immunology 183:7196-7203 – IF 4.886
• Müller AM, Martens UM, Hofmann S, Bruckner-Tuderman L, Mertelsmann R, Lübbert M (2006) Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Annals of Hematology 85:1-16 – IF 2.904
• Müller AM, Ihorst G, Waller CF, Dolken G, Finke J, Engelhardt M (2006) Intensive chemotherapy with autologous peripheral blood stem cell transplantation during a 10-year period in 64 patients with germ cell tumor. Biology of Blood and Marrow Transplantation 12:355-365 – IF 3.853
• Müller AM, Geibel A, Neumann H, Kühnemund A, Schmitt-Gräff A, Böhm J, Engelhardt M. (2006) Primary (AL) amyloidosis in plasma cell disorders. The Oncologist 11:824-830 – IF 5.025

Reviews

• Luginbuehl V, Abraham E, Kovar K, Flaaten R, Müller AMS. Better by design: What to expect from novel CAR-engineered cell therapies? Biotechnol Adv. 2022 Feb 9:107917. doi: 10.1016/j.biotechadv.2022.107917.
• Roth P, Winklhofer S, Müller AMS, Dummer R, Mair MJ, Gramatzki D, Le Rhun E, Manz MG, Weller M, Preusser M. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 2021 Jun;97:102189. doi: 10.1016/j.ctrv.2021.102189. Epub 2021 Mar 23. PMID: 3387297
• Ring A, Müller AM (2019) Chemotherapie-freie Behandlung von hämatologischen Neoplasien: Zukunftstraum oder beginnende Realität? Praxis 2019; 108(6):1-9
• Müller AM, Duque J, Shizuru JA, Lübbert M (2008) Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 27:5759-577 – IF 7.971
• Müller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005). Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Annals of Hematology 84:1-12 – IF 2.904
• Müller AM, Rawluk J, Thierry V, Brink I, Engelhardt M (2005) Innovative antibody-therapies for malignant lymphomas. Deutsche Medizinische Wochenschrift 130:2783-2788 – IF 0.569
• Hofmann SC, Technau K, Müller AM, Lübbert M, Bruckner-Tuderman L (2007). Bullous pemphigoid associated with hypereosinophilic syndrome: Simultaneous response to imatinib. Journal of the American Academy of Dermatology 56:S68-72 – IF 8.277

Case reports / Letters to the editor

• Koch C, Montrasio G, Scherr B, Schimmer R, Matter C, Bühler K, Manz MG, Müller AM. Fulminant Cardiotoxicity in a Patient with Cardiac Lymphoma Treated with CAR-T Cells. JACC Cardio Oncology, in press
• Rösler W, Bink A, Bissig M, Imbach L, Marques Maggio E, Manz MG, Müller T, Roth P, Rushing E, Widmer C, Zenz T, von Moos S, Müller AMS. CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS. Hemasphere. 2022 Jun 17;6(7):e733. doi: 10.1097/HS9.0000000000000733. eCollection 2022 Jul
• Utebay D, Seeger H, Müller AMS, David S. Complement inhibition for the treatment of COVID-19 triggered thrombotic microangiopathy with cardiac failure: a case report. Eur Heart J Case Rep. 2021 Sep 28;5(10):ytab386. doi: 10.1093/ehjcr/ytab386. eCollection 2021 Oct. PMID: 34661055
• Doerschner M, Pekar-Lukacs A, Messerli-Odermatt O, Dommann-Scherrer C, Rütti M, Müller AM, Nair G, Kamarachev J, Kerl K, Beer M, Messerli M, Frauenknecht K, Haralambieva E, Hoetzenecker W, French LE, Guenova E (2018) Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Br J Dermatol. 181(6):1296-1302 – IF 8.277
• Wehrli M, Oppliger Leibundgut E, Gattiker HH, Manz MG, Müller AM*, Goede JS* (*shared last authorship) (2017) Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement. Oncologist. 22(4):480-483 – IF 5.025
• Kiesel H, Müller AM, Schmitt-Graeff A, Veelken H (2009) Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations. (Bench-to-Bedside Report) Cancer Biology & Therapy 8:319-321 – IF 3.659
• Engelhardt M, Müller AM, Maier W, Wäsch R (2005) Severe irreversible bilateral hearing loss after bortezomib (VELCADE(R)) therapy in a multiple myeloma (MM) patient. (Correspondence) Leukemia 19:869-870 – IF 8.665
• Müller AM, Betz MJ, Kromeier J, Ghanem NA, Geibel A, Imdahl A, Frydrychowicz AP (2006) Acute pneumopericardium due to intestino-pericardial fistula. (Images in cardiovascular medicine) Circulation 114:e7-9 – IF 23.603

Book Chapters

• Müller AM, Florek M (2014) 5-Azacytidine/ Azacitidine. In: Recent Results in Cancer Research: Small Molecules in Oncology. Martens, U.M. (eds), pp. 299-324, Springer Berlin Heidelberg.
• Müller A, Zürcher G. (2008) Nutrition in Cancer Patients. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 225-234, Springer. Heidelberg Berlin New York
• Müller A, Scheele J. (2008) Inhibition of Angiogenesis. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 319-321, Springer. Heidelberg Berlin New York
• Scheele JS, Müller A, Martens U. (2008) Pharmacogenetics and Pharmacogenomics. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 201-203, Springer. Heidelberg Berlin New York
• Thierry V, Müller A, Engelhardt M, (2008) Growth Factors. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 218-224, Springer. Heidelberg Berlin New York

Editorials, other publication types

• Müller AMS (2022). Chronic GVHD on the Move, Blood à accepted, in press
• Müller AMS, Kumar SK, Bruno B (2019) The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all? Haematologica 104(2):222-225. (Editorial)
• Houot R, Pachynski R, Czerwinski DK, Goldstein MJ, Sagiv-Barfi I, Brody J, Müller AM, Marabelle A (2016) Holbrook Kohrt: In Memoriam (1977-2016). Clinical Cancer Research 22:3695-3696

Positions and Functions

• from 05/2022: Medical University of Vienna and General Hospital Vienna; University Professor for Cellular Therapy and Transfusion Medicine; Chair of the Department of Blood Group Serology and Transfusion Medicine
• 04/2012-04/2022: University Hospital Zurich and University Zurich
• 01/2020-04/2022: Senior attending with extended responsibilities in Medical Oncology and Hematology
• 06/2015-12/2019: Senior attending in Medical Oncology and Hematology, Stem cell transplantation / Cellular therapies
• Since 2018: Establishment and lead of CAR-T cell program
• 03/2017-04/2022: Medical head of clinical stem cell laboratory; Program director of autologous stem cell transplantation program
• 04/2016-04/2022: Establishment of a specialized, interdisciplinary clinic for patients with chronic Graft-versus-Host Disease

Clinical Education

• 08/2014: Board examination in Internal Medicine, Hematology and Oncology (Germany: Internistische Hämatologie & Onkologie)
• 04/2012-12/2014: Clinical Fellowship Hematology, University Hospital Zurich
• 06/2002-12/2005: Residency Internal Medicine, University Medical Center Freiburg, Department of Hematology/Oncology, Chair: Prof. R. Mertelsmann
• 1995-2002: Candidate for M.D., School of Medicine, Albert-Ludwigs University, Freiburg; Germany

Experimental and Clinical Research

• 11/2017: Habilitation in Hematology, “Friend or foe? – Donor T cells regulate hematopoietic stem cell and immune function following allogeneic hematopoietic cell transplantation”
• 2016 to 2022: Clinical study activities as «Local Principal Investigator”, mostly in the context of cellular therapies
• 01/2013 to 2022: Group leader in the Experimental Hematology Laboratory, University Hospital Zurich:
• 01/2010 to 03/2012: Research Associate, Division of Blood & Marrow Transplantation, Stanford University
• 2006 to 2009: Postdoctoral Fellowship: Division of Blood & Marrow Transplantation, Stanford University; Supervisor: Prof. J.A. Shizuru
• 1998-2002: Dissertation / ME thesis: Gene expression of annexin II and ribosomal protein LP23A and cytokine analysis in juvenile myelomonocytic leukemia. University Children’s Hospital Zurich, Hematology, thesis advisor Prof C.N. Niemeyer

Honors, awards, grants

• 2020: Basic Science Award of the European Society of Blood and Marrow Transplantation (EBMT) – “JUN activation in dermal fibroblasts promotes fibrosis and inflammation in sclerodermatous graft-vs-host disease in mice and humans”
• 2017: Support from the Swiss Transplant Cohort Study (STCS); project: Reconstitution of T cell immunity against cytomegalovirus (CMV) following allogeneic hematopoietic cell transplantation (HCT)
• 2017: Best Abstract Award at the Annual Meeting of the DGHO/OeGHO/SGMO und SGH (“Alloreactivity targets the bone marrow microenvironment following allogeneic hematopoietic cell transplantation”)
• 2015: Support from the PROMEDICA Foundation: “Wissenschaftliche Oberarztstelle” for 2 years: start 04/2016 (80% protected research time)
• 2014: Cancer League Zurich, Project funding “Intestinal microbial changes in patients with acute leukemias during chemotherapy”
• 2014: URPP (University Research Priority Program), Translational Cancer Research: “Reconstitution of blood & immune function, GVHD-, and GVL-effects – unraveling the complex relationships in the bone marrow after blood stem cell transplantation”
• 2014: SFK / Stiftung zur Förderung der Knochenmarktransplantation - Candy Heberlein Award; “Complex Interactions following allogeneic hematopoietic cell transplantation – Immunefunction, pharmacological immunosuppression, GVHD and CMV-reactivation”
• 2014: Transplantation-Center University Hospital Zurich: Award for best scientific experimental publication in transplantation
• 2014: Kurt & Senta Hermann Foundation: Project Funding “Reconstitution of blood formation and immune function, graft-vs-host disease and graft-vs-leukemia effects”
• 2013 to 2016: Project funding by the Swiss Cancer League for “Improving Graft-versus-tumor Effects by Donor Vaccination with WT1-peptide and Transplantation of Tailored Hematopoietic Grafts”
• 2006 to 2007: Postdoctoral Research Fellowship, German Research Foundation (“Murine models of chronic Graft-vs-Host Disease”)

Selected Memberships

• American Society of Hematology (ASH)
• European Hematology Association (EHA)
• Walter Siegenthaler Gesellschaft
• American Society of Transplantation and Cellular Therapies (ASTCT)
• Swiss Society of Hematology (SSH)
• Österreichische Gesellschaft für Blutgruppenserologie, Transfusionsmedizin, Regenerative Medizin und Immungenetik (ÖGBT)
• Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI)

• klinische Transfusionsmedizin
• Herstellungsleitung Blutkomponenten (Thrombozytenkonzentrate, Serum-Augentropfen)

• klinische Transfusionsmedizin
• Patient Blood Management
• transfusionsmedizinische Schwangerschaftsbetreuung

Positionen und Funktionen

• seit 10/2022 Leitung Patient Blood Management
• seit 10/2021 Stv. Herstellungsleitung Blutprodukte und Arzneimittel
• seit 07/2021 Stv. Strahlenschutzbeauftragte
• seit 2018 Mitarbeit am Projekt Stammzellspende MedUni Wien
• seit 2019 Sachkundige Person (AMG Qualified Person)
• seit 2015 Fachärztin für Blutgruppenserologie und Transfusionsmedizin

Ausbildung

• 2021 Ausbildung Strahlenschutzbeauftragte
• 2020 Ausbildung Qualified Person
• 2018 Notärztin (ÖÄK-Diplom)
• 2015 Fachärztin für Blutgruppenserologie und Transfusionsmedizin
• 2004–2015 Fachärzt:innenausbildung für Blutgruppenserologie und Transfusionsmedizin an der Medizinischen Universität Wien
• 1999–2004 Studium der Humanmedizin an der Medizinischen Universität Wien
• 1999 Abschluss an der Technischen Universität Wien